News for 'Safety Research'

SSLV's second flight scheduled in first quarter of this year: ISRO

SSLV's second flight scheduled in first quarter of this year: ISRO

Rediff.com1 Feb 2023

The SSLV is designed to be affordable and amenable to industry production and aimed to function as a launch-on-demand platform for mini, micro or nano satellites.

2 gorillas at US zoo test positive for COVID-19

2 gorillas at US zoo test positive for COVID-19

Rediff.com17 Jan 2021

According to the zoo, two of the gorillas had started coughing on Wednesday, following which San Diego Zoo Global initiated the process of testing fecal samples from them for SARS-CoV-2 through the California Animal Health and Food Safety Laboratory System.

How Adani Saga Affects Indian Banks

How Adani Saga Affects Indian Banks

Rediff.com27 Feb 2023

While the collapse of a large financial intermediary can wreak havoc on the system because of the interconnectivity, a large business conglomerate too can play spoilsport if the banks have too much exposure to the entity, explains Tamal Bandyopadhyay.

'Most countries won't forgive deaths of children'

'Most countries won't forgive deaths of children'

Rediff.com22 Nov 2022

'The deaths of the children in the Gambia would batter India's reputation as the developing world's pharmacy.'

1 in 4 experience mild side effects from Covishield: Lancet study

1 in 4 experience mild side effects from Covishield: Lancet study

Rediff.com28 Apr 2021

The researchers from King's College London in the United Kingdom also found that most systemic side effects -- meaning side effects excluding where the injection took place -- peaked within the first 24 hours following vaccination and usually lasted 1-2 days.

ISRO to kick off 2022 launch mission with PSLV-C52 on Feb 14

ISRO to kick off 2022 launch mission with PSLV-C52 on Feb 14

Rediff.com9 Feb 2022

The launch of Polar Satellite Launch Vehicle (PSLV-C52) is scheduled at 05:59 hours on Monday from the First Launch Pad of Satish Dhawan Space Centre, Sriharikota, the Bengaluru-headquartered space agency said.

'Unprecedented vaccine trial in India'

'Unprecedented vaccine trial in India'

Rediff.com23 Dec 2020

Bharat Biotech recruited 13,000 participants for the Phase-3 clinical trial of Covaxin. This is one of the largest efficacy trials held in the country.

WHO stops trial of anti-malarial drug for COVID-19 treatment

WHO stops trial of anti-malarial drug for COVID-19 treatment

Rediff.com26 May 2020

WHO director-general Tedros Adhanom Ghebreyesus said that in view of a paper published last week in the Lancet medical journal, that showed people taking hydroxychloroquine were at higher risk of death and heart problems than those that were not.

How long before the world gets a COVID-19 vaccine?

How long before the world gets a COVID-19 vaccine?

Rediff.com28 Apr 2020

More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.

Coronil case: HC asks Ramdev not to mislead people

Coronil case: HC asks Ramdev not to mislead people

Rediff.com17 Aug 2022

The Delhi high court Wednesday told Ramdev that while he was welcome to have his followers, he should not mislead the public by saying more than what is 'official'.

Russian crude will keep flowing into India at least till Dec

Russian crude will keep flowing into India at least till Dec

Rediff.com14 Dec 2022

India will need to travel back in time and seek inspiration from football greats Tulsidas Balaram and Chuni Goswami to deftly dribble around and sidestep the West-imposed price cap on exports of Russian seaborne crude oil. India depends on imported oil to meet 86 per cent of its needs, of which nearly a quarter now comes from Russia. The copious flows are roughly 10 per cent cheaper than competing suppliers helping India save billions of dollars in fuel costs.

'ICMR fast tracking Covid vaccine for PM announcement on I-Day'

'ICMR fast tracking Covid vaccine for PM announcement on I-Day'

Rediff.com4 Jul 2020

'Forcing the development of an indigenous vaccine as a cure for COVID-19, bypassing all health & safety norms, to be announced by PM Modi on Independence Day is fraught with horrendous human costs'

India's first COVID-19 vaccine gets nod for human trials

India's first COVID-19 vaccine gets nod for human trials

Rediff.com30 Jun 2020

COVAXIN, developed by Hyderabad-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, has got the nod for human clinical trials from the Drug Controller General of India

Covaxin emergency use decision likely in 4-6 weeks: WHO

Covaxin emergency use decision likely in 4-6 weeks: WHO

Rediff.com10 Jul 2021

There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan said.

Time to book PROFITS in stock markets?

Time to book PROFITS in stock markets?

Rediff.com8 Nov 2021

Even if the bull run may continue, most experts say some profit booking is called for, points out Sanjay Kumar Singh.

India's entry-level cars lose steam as buyers wait it out in inflation

India's entry-level cars lose steam as buyers wait it out in inflation

Rediff.com31 May 2022

The economy segment of India's car market is unlikely to revive soon term as inflation and prices prompt buyers to defer purchases. The share of entry-level cars in the passenger vehicle market dropped to the lowest in seven years at the end of the Financial Year 2021-22 (FY22). A recovery in the segment will be largely driven by the overall economic growth, improvement in income levels, and easing of semiconductor shortage, say carmakers and analysts.

Data traffic in India increased 60 times in 5 years

Data traffic in India increased 60 times in 5 years

Rediff.com12 Feb 2021

A Nokia research showed that 4G alone constituted nearly 99 per cent of the total data traffic consumed across the country in 2020.

Experts welcome WHO's decision to resume HCQ clinical trial

Experts welcome WHO's decision to resume HCQ clinical trial

Rediff.com4 Jun 2020

The global heath body had earlier suspended the hydroxychloroquine arm of the clinical trials of experimental COVID-19 drugs over safety concerns.

Life is tough for India's gig workers

Life is tough for India's gig workers

Rediff.com13 Feb 2022

The recent protests by employees of Urban Company and the case of a a Zomato delivery executive who died in a road accident point to the severely straitened condition of gig workers during the ongoing Covid-19 pandemic. Budget 2021 had promised several measures to help the cause of gig economy workers, but most of them are yet to see the light of day. Even after a year, the country's gig workers continue to be without any social security cover or a minimum wage guarantee. "In Budget 2021, finance minister Nirmala Sitharaman had announced that the government is looking toward including migrant and gig workers for social security benefits," says Srinivas Kotni, managing partner, Lexport, a consulting firm. Parliament had passed the Code on Wages in 2019 and Code on Industrial Relations, Social Security and Occupational Safety, Health and Working Conditions in 2020.

Threat of surface Covid transmission increases in winter

Threat of surface Covid transmission increases in winter

Rediff.com18 Dec 2020

Scientists have used virus-like particles to predict how environmental factors affect the survival of the novel coronavirus on surfaces, and found that the COVID-19 virus may remain infectious longer as temperatures drop in winter.

Final analysis: Covaxin 65.2% effective against Delta variant

Final analysis: Covaxin 65.2% effective against Delta variant

Rediff.com3 Jul 2021

Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

Covishield accounts for 88% of Covid jabs in India

Covishield accounts for 88% of Covid jabs in India

Rediff.com1 Jan 2022

Serum Institute has the capacity to make 250 million doses of Covishield monthly.

Can avocados help delay diabetes?

Can avocados help delay diabetes?

Rediff.com27 Nov 2019

Avocation B (AvoB), a fat molecule found only in avocados counters incomplete oxidation in skeletal muscle and the pancreas to reduce insulin resistance.

How govt will judge the performance of PSUs

How govt will judge the performance of PSUs

Rediff.com11 May 2022

The number of times public sector undertakings (PSUs) have held conference calls with investors, their capital management, and debt financing are among the parameters that the Centre will use to judge their performance for the first time, a senior official in the know said. The government will evaluate PSUs for FY22 based on new parameters that were finalised by the Department of Public Enterprises (DPE) in consultation with the Department of Investment and Public Asset Management (DIPAM) last year, the official said. The government had included more conditions in the memorandum of understandings (MoUs) - used to set annual targets - that public sector enterprises sign with the DPE every year. These included a consistent dividend policy, which seeks to transfer dividends by PSUs every quarter; and market capitalisation or share price improvement over the sectoral index on an annual average basis for listed companies.

'Everybody's going to get infected'

'Everybody's going to get infected'

Rediff.com27 Dec 2021

'In the likelihood that Omicron is circulating, you have a much greater chance of getting infected now, than you did during the Age of Delta.'

Sensex slides by 135 points as markets fall for 6th straight day

Sensex slides by 135 points as markets fall for 6th straight day

Rediff.com17 Jun 2022

Market benchmarks gave up intra-day gains to close in the red for the sixth session on the trot on Friday, capping a bruising week which saw a massive dash for safety amid rate hikes by global central banks and fears of slowing growth.

Let Dalits possess arms for their safety: Athawale tells Maha govt

Let Dalits possess arms for their safety: Athawale tells Maha govt

Rediff.com28 Jan 2016

In the backdrop of suicide of a Dalit research scholar in Hyderabad University, Rajya Sabha Member of Parliament Ramdas Athawale today demanded that members of the community be allowed to possess firearms given a "vertical rise" in incidents of "atrocities" against them.

Gennova's mRNA Covid vaccine gets nod for Phase 2-3 trials

Gennova's mRNA Covid vaccine gets nod for Phase 2-3 trials

Rediff.com25 Aug 2021

If things go according to plan, the vaccine would be available in the market by the end of this year.

When will Covid end? Here's what experts say

When will Covid end? Here's what experts say

Rediff.com15 Feb 2022

'Unless we see four weeks of low and stable numbers with only minor fluctuations, we cannot call the valley as endemic just as yet'

Cyclone Yaas: DRDO to protect missile testing facilities

Cyclone Yaas: DRDO to protect missile testing facilities

Rediff.com25 May 2021

The Integrated Test Range of Defence Research and Development Organisation (DRDO) has taken various measures to protect its facilities at Chandipur and Abdul Kalam Island in Odisha, which are likely to be affected by cyclone 'Yaas', an official said.

Furore over 'Rashtrapatni' remark reignites gender debate

Furore over 'Rashtrapatni' remark reignites gender debate

Rediff.com28 Jul 2022

In the last 75 years, there have been multiple calls for a gender-neutral term for the head of the State and debates over it.

New technology adds zing to Indian Railways

New technology adds zing to Indian Railways

Rediff.com4 Mar 2020

Globally, London's Tube and French railway networks are already using this technology in their corrosion-prone areas.

World could enter worst part of pandemic: Bill Gates

World could enter worst part of pandemic: Bill Gates

Rediff.com22 Dec 2021

Gates, 66, on Tuesday, said that "I know it's frustrating to go into another holiday season with COVID looming over us. But it won't be like this forever. Someday the pandemic will end, and the better we look after each other, the sooner that time will come."

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Despite Jammu attack India set to relax drone policy

Despite Jammu attack India set to relax drone policy

Rediff.com14 Jul 2021

While there were concerns about the security aspect of drones, top government officials were of the view that restricting the drone industry would stifle a sunrise sector which holds significant promise for future, reports Arindam Majumder.

Govt may defer LIC IPO to next fiscal amid Ukraine crisis

Govt may defer LIC IPO to next fiscal amid Ukraine crisis

Rediff.com6 Mar 2022

The government is expected to defer the mega initial public offering (IPO) of LIC to the next financial year as the ongoing Russia-Ukraine war has dampened fund managers' interest in the public issue, market experts said on Sunday. The government was looking to sell 5 per cent stake in Life Insurance Corporation (LIC) this month, which could have fetched over Rs 60,000 crore to the exchequer. The IPO would have helped meet the curtailed divestment target of Rs 78,000 crore this fiscal.

F1 boss breaks silence on Hamilton's jewellery battle

F1 boss breaks silence on Hamilton's jewellery battle

Rediff.com16 May 2022

Lewis Hamilton and the FIA were in a standoff at this month's Miami Grand Prix over piercings

'If junk stocks are rising, one has to be careful'

'If junk stocks are rising, one has to be careful'

Rediff.com16 Dec 2020

'Investors should put their money in stocks where the margin of safety is high.'

WHO to decide next week on approval to Covaxin

WHO to decide next week on approval to Covaxin

Rediff.com5 Oct 2021

'WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin,' the global health body tweeted.

Covaxin's 50 pc efficacy adequate for Covid, say experts

Covaxin's 50 pc efficacy adequate for Covid, say experts

Rediff.com26 Nov 2021

The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.